Indapamide
Indapamide (indapamide) is a small molecule pharmaceutical. Indapamide was first approved as Lozol on 1983-07-06. It is used to treat edema, heart failure, hypertension, and nephrotic syndrome in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Indapamide (discontinued: Indapamide, Lozol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| indapamide | ANDA | 2026-01-26 |
| widaplik | New Drug Application | 2025-08-20 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03B: Low-ceiling diuretics, excl. thiazides
— C03BA: Sulfonamides, low-ceiling diuretics, plain
— C03BA11: Indapamide
— C09: Agents acting on the renin-angiotensin system
— C09B: Ace inhibitors, combinations
— C09BX: Ace inhibitors, other combinations in atc
— C09BX01: Perindopril, amlodipine and indapamide
— C10: Lipid modifying agents
— C10B: Lipid modifying agents, combinations
— C10BX: Lipid modifying agents in combination with other drugs
— C10BX13: Rosuvastatin, perindopril and indapamide
HCPCS
No data
Clinical
Clinical Trials
73 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 5 | 14 | 20 | 13 | 53 |
| Essential hypertension | D000075222 | — | I10 | 1 | 3 | 4 | 1 | — | 9 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 1 | 1 | 4 | 7 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 1 | 3 | 1 | 6 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | 3 | — | 4 |
| Cerebral small vessel diseases | D059345 | — | — | — | — | 1 | 1 | 1 | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | 1 | 1 | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | 1 | 2 |
| Pathologic constriction | D003251 | — | — | — | — | — | 1 | 1 | 2 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | — | 1 | — | 2 |
Show 13 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral hemorrhage | D002543 | — | — | — | — | 2 | — | 1 | 3 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | 1 | — | 2 | 3 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 1 | — | 1 | 2 |
| Vascular dementia | D015140 | — | F01 | — | — | 1 | — | 1 | 2 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 1 | — | 1 | 2 |
| Hemorrhagic stroke | D000083302 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | — | — | — | 1 | — | — | 2 | 3 |
| Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | 1 | — | — | 1 | 2 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | 1 | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | 1 | — | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | — | 1 | — | — | — | 1 |
| Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 3 | — | — | — | — | 3 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 1 | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 1 | 1 |
| Stents | D015607 | — | — | — | — | — | — | 1 | 1 |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
| Critical illness | D016638 | — | — | — | — | — | — | 1 | 1 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Blood pressure | D001794 | EFO_0004325 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Indapamide |
| INN | indapamide |
| Description | Indapamide is a sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine. It has a role as an antihypertensive agent and a diuretic. It is a member of indoles, an organochlorine compound and a sulfonamide. It is functionally related to a benzamide. |
| Classification | Small molecule |
| Drug class | diuretics (sulfamoylbenzoic acid derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 26807-65-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL406 |
| ChEBI ID | 5893 |
| PubChem CID | 3702 |
| DrugBank | DB00808 |
| UNII ID | F089I0511L (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Indapamide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,728 documents
View more details
Safety
Black-box Warning
Black-box warning for: Widaplik
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,895 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use